In the final segment of our roundtable series, the panelists discuss the treatment of CRPC, focusing on metastatic disease.
ESMO 2024: Focus on Prostate Cancer
In the fifth segment of our roundtable series, the treatment of patients with CRPC is discussed.
In the fourth part of our series, the panelists discuss PROs and potential patient comorbidities.
In the third part of this series, disparities and the optimization of care is discussed, along with the use of ADT and ARPIs.
In the second segment of our roundtable series, the panelists discuss their approaches to the use of PSMA PET for patients.
In the first part of this series, the panel discusses treatments in the post-salvage setting and review therapeutic options.
Dr. Oliver Sartor gives an overview of the SPLASH trial on PSMA-targeted therapies for patients with prostate cancer.
Dr. Gerhardt Attard discusses the benefits of the Decipher score as utilized during the STAMPEDE trial.
The Decipher score demonstrated a notable benefit in predicting patient survival rates during the STAMPEDE trial.
Dr. Gerhardt Attard provides insight on the STAMPEDE study, along with the Decipher score used during the trial.
Experts at ESMO Congress 2024 discuss novel therapies for castration-resistant prostate cancer.
Experts review the CONTACT-02 trial as well as the Decipher score utilized in the STAMPEDE trial.
The roundtable of experts discuss the realities of the SPLASH trial's hazard ratio and overall survival results.
At ESMO 2024, experts discuss androgen-deprivation therapy in HSPC as well as the ARANOTE trial.
Experts at ESMO 2024 discuss the implications and insights associated with the Peace III trial.
Experts discuss mHSPC discuss risk stratification, developed novel approaches for treatment, and treatment sequencing.
Drs. Samantha Armstrong and Karine Tawagi provide updated commentary on STAMPEDE, SunRISe-4, and SUNNIFORECAST trials.
Dr. Armstrong reviews a handful of GU studies presented, including NIAGRA and STAMPEDE.
Drs. Tawagi and Wallis review the PEACE-III, STAMPEDE, UpFrontPSMA, and SPLASH studies trials at the ESMO Congress 2024.
SPLASH continues to show benefit for PSMA RLT in mCRPC and adds to this consideration in the pre-chemotherapy setting.
The final results of the CONTACT-02 trial show favorable, but not statistically significant, benefit for cabo/atezo in mCRPC.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.